Newsroom

Sorted by: Latest

-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF 10% - January 12.02.2026 FJAN.LN IE000MDKBOB3 200,002.00 USD 5,443,280.10 27.216  ...
-

MEDIPOST Inc. Submits IND Amendment With U.S. Food and Drug Administration to Initiate Phase III Trial

CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, announced today that it has filed an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration (FDA) to support the initiation of a Phase III clinical trial evaluating its investigational cell therapy for knee osteoarthritis.  MEDIPOST’s investigational therapy is an umbilical cord...
-

Cove Kaz Capital Group and Tau-Ken Samruk Execute Definitive Agreements to Develop the World’s Largest Known Undeveloped Tungsten Resource

ASTANA, Kazakhstan & NEW YORK--(BUSINESS WIRE)--Cove Kaz Capital Group (“Cove Kaz” or “the Company”), a portfolio company of Cove Capital LLC, is pleased to announce that it has executed definitive transaction documents with Tau-Ken Samruk National Mining Company, including a Share Purchase Agreement (SPA) and Shareholders’ Agreement (SHA), to advance the development of the Northern Katpar and Upper Kairakty tungsten deposits in Kazakhstan. Under the joint venture structure, Cove Kaz will hold...
-

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the completion of patient enrollment in its Phase 2 proof-of-concept clinical trial evaluating ALTO-101, a novel, transdermal phosphodiesterase-4 (PDE4) inhibitor, for the treatment of cognitive impairment associated with schizophrenia (CIAS). Topline data from the...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Nasdaq Clean Edge Global Water UCITS ETF 12.02.2026 H2O LN IE000Q8F0M81 550,002.00 USD 11,874,815.92 21.591  ...
-

Veradigm Brings Patient Voice to Healthcare Research with New Real-World Data Survey Solution

CHICAGO--(BUSINESS WIRE)--Veradigm (OTCMKTS:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today announced a new patient‑reported outcomes (PRO) survey capability that brings the patient voice directly into real‑world evidence generation. The new solution gives life sciences organizations timely, privacy‑preserving insights directly from patients, adding essential context to clinical and observational research. Built on Veradigm’s FollowMyHealth pat...
-

Designer Antthony Mark Hankins Files Federal Lawsuit Following Termination of Long-Standing Retail Partnership

SAVANNAH, Ga.--(BUSINESS WIRE)--Antthony Mark Hankins, founder of Antthony Design Originals, has filed a federal lawsuit against QVC and HSN....
-

CBL Properties Reports Outstanding Results for Fourth Quarter and Full-Year 2025

CHATTANOOGA, Tenn.--(BUSINESS WIRE)--CBL Properties (NYSE: CBL) announced results for the fourth quarter and year ended December 31, 2025. Results of operations as reported in the consolidated financial statements for these periods are prepared in accordance with GAAP. A description of each supplemental non-GAAP financial measure and the related reconciliation to the comparable GAAP financial measure is located at the end of this news release.     Three Months Ended December 31,     Year Ended...